Browse KHK

Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00294 pfkB family carbohydrate kinase
Function

Catalyzes the phosphorylation of the ketose sugar fructose to fructose-1-phosphate.

> Gene Ontology
 
Biological Process GO:0005996 monosaccharide metabolic process
GO:0006000 fructose metabolic process
GO:0006001 fructose catabolic process
GO:0006081 cellular aldehyde metabolic process
GO:0009743 response to carbohydrate
GO:0009744 response to sucrose
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009750 response to fructose
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010043 response to zinc ion
GO:0016052 carbohydrate catabolic process
GO:0019318 hexose metabolic process
GO:0019320 hexose catabolic process
GO:0019682 glyceraldehyde-3-phosphate metabolic process
GO:0032868 response to insulin
GO:0034284 response to monosaccharide
GO:0034285 response to disaccharide
GO:0043434 response to peptide hormone
GO:0044262 cellular carbohydrate metabolic process
GO:0044282 small molecule catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046365 monosaccharide catabolic process
GO:0046835 carbohydrate phosphorylation
GO:0061624 fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate
GO:1901652 response to peptide
GO:1990267 response to transition metal nanoparticle
Molecular Function GO:0004454 ketohexokinase activity
GO:0019200 carbohydrate kinase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00051 Fructose and mannose metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-70350: Fructose catabolism
R-HSA-5652084: Fructose metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KHK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KHK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KHK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1350.77
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1030.933
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3260.663
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9790.0436
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4690.694
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.6240.253
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0420.913
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1490.832
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1750.835
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0070.997
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5690.854
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1930.179
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KHK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KHK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KHK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KHK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KHK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KHK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KHK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKHK
Nameketohexokinase (fructokinase)
Aliases hepatic fructokinase; Ketohexokinase
Chromosomal Location2p23.3-p23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KHK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.